Quanterix (QTRX) Stock Price, News & Analysis

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Quanterix in the last twelve months. There are currently 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" QTRX shares.
View QTRX analyst ratings or view top-rated stocks.

6 equities research analysts have issued 12-month price objectives for Quanterix's shares. Their QTRX share price targets range from $30.00 to $34.00. On average, they predict the company's share price to reach $32.00 in the next twelve months. This suggests a possible upside of 102.1% from the stock's current price.
View analysts price targets for QTRX or view top-rated stocks among Wall Street analysts.

Quanterix's stock was trading at $27.34 on January 1st, 2024. Since then, QTRX shares have decreased by 42.1% and is now trading at $15.83.
View the best growth stocks for 2024 here.

Quanterix saw a decline in short interest during the month of March. As of March 31st, there was short interest totaling 1,000,000 shares, a decline of 18.7% from the March 15th total of 1,230,000 shares. Based on an average daily volume of 334,600 shares, the days-to-cover ratio is currently 3.0 days. Approximately 2.9% of the company's shares are short sold.
View Quanterix's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our QTRX earnings forecast.

Quanterix Co. (NASDAQ:QTRX) issued its earnings results on Thursday, February, 29th. The company reported ($0.33) EPS for the quarter, missing analysts' consensus estimates of ($0.28) by $0.05. The business had revenue of $31.55 million for the quarter, compared to analysts' expectations of $27.92 million. Quanterix had a negative net margin of 26.42% and a negative trailing twelve-month return on equity of 9.15%.

First Trust Nasdaq Lux Digital Health Solutions ETF holds 444 shares of QTRX stock, representing 0.30% of its portfolio.

Quanterix issued an update on its FY 2024 earnings guidance on Thursday, February, 29th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $139.0 million-$144.0 million, compared to the consensus revenue estimate of $138.2 million.

15 employees have rated Quanterix Chief Executive Officer Kevin Hrusovsky on Glassdoor.com. Kevin Hrusovsky has an approval rating of 70% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Quanterix investors own include Editas Medicine (EDIT), Novavax (NVAX), Akoustis Technologies (AKTS), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), Walt Disney (DIS), Illumina (ILMN), Sorrento Therapeutics (SRNE), Cisco Systems (CSCO) and Intellia Therapeutics (NTLA).

Quanterix (QTRX) raised $50 million in an initial public offering on Thursday, December 7th 2017. The company issued 3,300,000 shares at a price of $14.00-$16.00 per share. J.P. Morga and Leerink Partners acted as the underwriters for the IPO and BTIG and Evercore ISI were co-managers.

Quanterix's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.05%) and Allspring Global Investments Holdings LLC (0.03%). Insiders that own company stock include Amol Chaubal, David C Duffy, David C Duffy, David R Walt, Dawn Mattoon, E Kevin Hrusovsky, John J Fry, John J Fry, Laurie J Olson, Marijn E Dekkers, Mark T Roskey, Mark T Roskey, Masoud Toloue, Michael A Doyle and William P Donnelly.
View institutional ownership trends.

Shares of QTRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.